Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Background The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m(2)) are unknown. Methods In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiova...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC gastroenterology 2020-11, Vol.20 (1), p.368-368, Article 368
Hauptverfasser: Iritani, Soichi, Akuta, Norio, Kawamura, Yusuke, Kajiwara, Akira, Kasuya, Kayoko, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saito, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The prognostic factors of morbidity and mortality in patients with lean NAFLD (body mass index < 25.0 kg/m(2)) are unknown. Methods In this retrospective study, 446 Japanese patients with histopathologically-confirmed NAFLD (lean NAFLD, n = 170) were followed for liver events, cardiovascular events, type 2 diabetes mellitus, and non-liver malignancies. The median observation period was 4.6 years. We also investigated the predictors of severe fibrosis (stage 3-4) and mortality in lean NAFLD patients. Results Glycolipid metabolic markers, liver function tests, NAFLD fibrosis score (NFS), and histological scoring were significantly lower in lean NAFLD patients than in non-lean NAFLD. The incidence of liver cancer was higher while that of T2DM was lower in lean NAFLD. Kaplan-Meier analysis showed no significant difference in overall survival between the lean and non-lean NAFLD. Multivariate analysis of data of lean NAFLD identified NFS >= - 1.455 as significant independent predictor of severe fibrosis, while history of liver cancer and NFS >= - 1.455 were predictors of overall survival. Conclusions Although patients with lean NAFLD have better histopathological and biochemical profile compared to patients with non-lean NAFLD, the prognosis is not different between the two groups. Lean NAFLD patients with NFS >= - 1.455 or history of liver cancer should be monitored carefully during follow-up.
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-020-01509-3